Add On Treatment for Cognitive Deficits in Schizophrenia

Model scores of the 29,894 trials active now.

Model score 12% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 12% of the time (145 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2010-11-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Design: crossover (lowers risk) · Design
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: headpfstableriskmonths
  Phrases that lowered it: subjects whokgmoderateimpairmentbody
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Responsible party: not given (raises risk) · Design
• Sponsor's past termination rate: 9.6% (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Has a data monitoring committee: No (lowers risk) · Design
• Maximum age: 40 (raises risk) · Who can join
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Sponsor's past trials: 83 (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 64 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Disease area, neurology: No (lowers risk) · Disease area
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia NCT01854944 · started 2013 · scored riskier than 25% of active trials completed
• A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia NCT01940159 · started 2013 · scored riskier than 27% of active trials completed
• Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia NCT03397134 · started 2017 · scored riskier than 23% of active trials completed
• Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy NCT01714661 · started 2012 · scored riskier than 72% of active trials completed
• Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy NCT01716975 · started 2012 · scored riskier than 72% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.